Subtyping of intraductal papillary mucinous neoplasms - pitfalls of MUC1 immunohistochemistry

Pia Klausen; Bojan Kovacevic; Anders Toxværd; Evangelos Kalaitzakis; John Gásdal Karstensen; Charlotte Vestrup Rift; Carsten Palnæs Hansen; Jan Storkholm; Peter Vilmann; Jane Preuss Hasselby

doi:10.1111/apm.12900

Subtyping of intraductal papillary mucinous neoplasms - pitfalls of MUC1 immunohistochemistry

Pia Klausen, Bojan Kovacevic, Anders Toxværd, Evangelos Kalaitzakis, John Gásdal Karstensen, Charlotte Vestrup Rift, Carsten Palnæs Hansen, Jan Storkholm, Peter Vilmann, Jane Preuss Hasselby

Institut for Klinisk Medicin

8 Citationer (Scopus)

Abstract

Intraductal papillary mucinous neoplasms (IPMNs) are precursor lesions of pancreatic ductal adenocarcinoma (PDAC). Current edition of WHO Classification of Tumors of the Digestive System recognizes four different subtypes (gastric, intestinal, pancreatobiliary, and oncocytic) and recommends analysis of mucin expression (MUC1, MUC2, MUC5AC, MUC6) as well as evaluation of architectural and cell differentiation patterns for correct classification. However, there is no consensus on MUC1 expression of IPMN-lesions in the literature. Current recommendations are based on studies where antibodies against the core MUC1 protein or sialylated MUC1 (tumor associated MUC1), not the fully glycosylated MUC1 were used. We have recently reported that MUC1 is strongly expressed in both gastric and intestinal types IPMN specimens from the cystic wall, obtained by endoscopic ultrasound guided microbiopsy procedure. We have used a commercial MUC1 antibody, validated and recommended for diagnostic use, which recognizes fully glycosylated MUC1. Based on the above, we propose a revision of the WHO Classification, specifying that antibodies against tumor associated MUC1 should be used for IPMN subtyping.

Originalsprog	Engelsk
Tidsskrift	A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica
Vol/bind	127
Udgave nummer	1
Sider (fra-til)	27-32
Antal sider	6
ISSN	0903-4641
DOI	https://doi.org/10.1111/apm.12900
Status	Udgivet - jan. 2019

Adgang til dokumentet

10.1111/apm.12900

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/apm.12900

Citationsformater

Klausen, P., Kovacevic, B., Toxværd, A., Kalaitzakis, E., Karstensen, J. G., Rift, C. V., Hansen, C. P., Storkholm, J., Vilmann, P., & Hasselby, J. P. (2019). Subtyping of intraductal papillary mucinous neoplasms - pitfalls of MUC1 immunohistochemistry. A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica, 127(1), 27-32. https://doi.org/10.1111/apm.12900

Klausen, P, Kovacevic, B, Toxværd, A, Kalaitzakis, E, Karstensen, JG, Rift, CV, Hansen, CP, Storkholm, J, Vilmann, P & Hasselby, JP 2019, 'Subtyping of intraductal papillary mucinous neoplasms - pitfalls of MUC1 immunohistochemistry', A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica, bind 127, nr. 1, s. 27-32. https://doi.org/10.1111/apm.12900

@article{6811dcd9466b4400b6107c2c9d96ded0,

title = "Subtyping of intraductal papillary mucinous neoplasms - pitfalls of MUC1 immunohistochemistry",

abstract = "Intraductal papillary mucinous neoplasms (IPMNs) are precursor lesions of pancreatic ductal adenocarcinoma (PDAC). Current edition of WHO Classification of Tumors of the Digestive System recognizes four different subtypes (gastric, intestinal, pancreatobiliary, and oncocytic) and recommends analysis of mucin expression (MUC1, MUC2, MUC5AC, MUC6) as well as evaluation of architectural and cell differentiation patterns for correct classification. However, there is no consensus on MUC1 expression of IPMN-lesions in the literature. Current recommendations are based on studies where antibodies against the core MUC1 protein or sialylated MUC1 (tumor associated MUC1), not the fully glycosylated MUC1 were used. We have recently reported that MUC1 is strongly expressed in both gastric and intestinal types IPMN specimens from the cystic wall, obtained by endoscopic ultrasound guided microbiopsy procedure. We have used a commercial MUC1 antibody, validated and recommended for diagnostic use, which recognizes fully glycosylated MUC1. Based on the above, we propose a revision of the WHO Classification, specifying that antibodies against tumor associated MUC1 should be used for IPMN subtyping.",

keywords = "Antigens, Neoplasm/analysis, Glycosylation, Humans, Immunohistochemistry/methods, Mucin-1/analysis, Pancreatic Intraductal Neoplasms/classification",

author = "Pia Klausen and Bojan Kovacevic and Anders Toxv{\ae}rd and Evangelos Kalaitzakis and Karstensen, {John G{\'a}sdal} and Rift, {Charlotte Vestrup} and Hansen, {Carsten Paln{\ae}s} and Jan Storkholm and Peter Vilmann and Hasselby, {Jane Preuss}",

year = "2019",

month = jan,

doi = "10.1111/apm.12900",

language = "English",

volume = "127",

pages = "27--32",

journal = "A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica",

issn = "0903-4641",

publisher = "Wiley Online",

number = "1",

}

TY - JOUR

T1 - Subtyping of intraductal papillary mucinous neoplasms - pitfalls of MUC1 immunohistochemistry

AU - Klausen, Pia

AU - Kovacevic, Bojan

AU - Toxværd, Anders

AU - Kalaitzakis, Evangelos

AU - Karstensen, John Gásdal

AU - Rift, Charlotte Vestrup

AU - Hansen, Carsten Palnæs

AU - Storkholm, Jan

AU - Vilmann, Peter

AU - Hasselby, Jane Preuss

PY - 2019/1

Y1 - 2019/1

N2 - Intraductal papillary mucinous neoplasms (IPMNs) are precursor lesions of pancreatic ductal adenocarcinoma (PDAC). Current edition of WHO Classification of Tumors of the Digestive System recognizes four different subtypes (gastric, intestinal, pancreatobiliary, and oncocytic) and recommends analysis of mucin expression (MUC1, MUC2, MUC5AC, MUC6) as well as evaluation of architectural and cell differentiation patterns for correct classification. However, there is no consensus on MUC1 expression of IPMN-lesions in the literature. Current recommendations are based on studies where antibodies against the core MUC1 protein or sialylated MUC1 (tumor associated MUC1), not the fully glycosylated MUC1 were used. We have recently reported that MUC1 is strongly expressed in both gastric and intestinal types IPMN specimens from the cystic wall, obtained by endoscopic ultrasound guided microbiopsy procedure. We have used a commercial MUC1 antibody, validated and recommended for diagnostic use, which recognizes fully glycosylated MUC1. Based on the above, we propose a revision of the WHO Classification, specifying that antibodies against tumor associated MUC1 should be used for IPMN subtyping.

AB - Intraductal papillary mucinous neoplasms (IPMNs) are precursor lesions of pancreatic ductal adenocarcinoma (PDAC). Current edition of WHO Classification of Tumors of the Digestive System recognizes four different subtypes (gastric, intestinal, pancreatobiliary, and oncocytic) and recommends analysis of mucin expression (MUC1, MUC2, MUC5AC, MUC6) as well as evaluation of architectural and cell differentiation patterns for correct classification. However, there is no consensus on MUC1 expression of IPMN-lesions in the literature. Current recommendations are based on studies where antibodies against the core MUC1 protein or sialylated MUC1 (tumor associated MUC1), not the fully glycosylated MUC1 were used. We have recently reported that MUC1 is strongly expressed in both gastric and intestinal types IPMN specimens from the cystic wall, obtained by endoscopic ultrasound guided microbiopsy procedure. We have used a commercial MUC1 antibody, validated and recommended for diagnostic use, which recognizes fully glycosylated MUC1. Based on the above, we propose a revision of the WHO Classification, specifying that antibodies against tumor associated MUC1 should be used for IPMN subtyping.

KW - Antigens, Neoplasm/analysis

KW - Glycosylation

KW - Humans

KW - Immunohistochemistry/methods

KW - Mucin-1/analysis

KW - Pancreatic Intraductal Neoplasms/classification

U2 - 10.1111/apm.12900

DO - 10.1111/apm.12900

M3 - Journal article

C2 - 30549137

SN - 0903-4641

VL - 127

SP - 27

EP - 32

JO - A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica

JF - A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica

IS - 1

ER -

Subtyping of intraductal papillary mucinous neoplasms - pitfalls of MUC1 immunohistochemistry

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater